Divi’s Labs Q3FY22 Results: Pharma major’s profit nearly doubles to Rs 902 cr; margins grow YoY basis

Pharmaceutical major Divi’s Laboratories on Friday reported a robust October-December quarter earnings for the financial year 2021-22 (Q3FY22). The company’s net profit almost doubled during the quarter, while revenue and margins grew year-on-year basis during the quarter. 

According to the company’s filing with exchanges, “Divi's Laboratories has earned a consolidated total income of Rs 2510 crore for the third quarter of the current year as against a total income of Rs 1721 crore during the corresponding quarter of last year, reflecting a growth of 46 per cent.” 

While the Profit after Tax (PAT) for the December-end quarter grew by 92 per cent to Rs 902 crore as against a PAT of Rs 471 crore for the corresponding quarter of last year, the filing said. 

The company’s Profit before Tax (PBT) for the quarter grew by 61 per cent to Rs 1034 crore, as against Rs 642 crore during the corresponding quarter of last year, Divis Lab said in a release. While the index heavyweight’s Q3FY22 margins expanded to 44 per cent from 40.6 per cent YoY.